Independent editorial publication
Editions · September 6, 2026
A clearer view of human progress.
Editorial illustration. This image does not depict the actual event.
In a 500-patient trial, median overall survival reached 13.2 months with daraxonrasib, compared with 6.7 months for standard chemotherapy. The FDA has now approved the first-in-class RAS inhibitor for specified adults with metastatic pancreatic cancer.
Read the storyIn the first patient of an ongoing UCL-UCLH clinical trial, an AI system analyzed live surgical video and highlighted critical structures while the surgeon remained in control. The tumor was removed and the patient's vision improved.
Read the storyBy the end of 2023, cameras had recorded more than 25,000 safe wildlife crossings at completed I-90 Snoqualmie Pass structures—including thousands of elk, deer and coyotes.
Read the storyThirty big cats have begun journeys from the former Luján Zoo to accredited sanctuaries in South Africa and Colorado. More than 20 animals still need permanent homes.
Read the storyA UNICEF-UNHCR program exceeded its water-service target across displacement-affected communities in Ethiopia, Somalia and Sudan while reducing interruptions and production costs in participating areas.
Read the storyThis Week in History
1977September 5Launched on September 5, 1977, Voyager 1 transformed our understanding of Jupiter and Saturn, became the first human-made object in interstellar space and remains an active extended mission.
Read the storyThe Weekly Good
A thoughtful selection of meaningful positive developments, designed for a quiet Sunday morning.
Newsletter signup is not active yet.